Company intelligence / Profile preview
NEOK Bio
Palo Alto, California, United Statesneokbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
NEOK Bio has two bispecific antibody-drug conjugates in preclinical development for solid tumors, aiming to enhance safety and efficacy by dual-targeting complementary tumor antigens using proprietary linker-payload technology. IND filings are planned by early 2026, with Phase 1 trials set for mid-2026 and initial data in 2027[1][2][4][5].
- Therapeutic areas
- Oncology
- Modalities
- Bispecific monoclonal antibodyAntibody-drug conjugate
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
ABL Bio
Beyond the preview
Go deeper on NEOK Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NEOK Bio.